News Search Results
Mar 18, 2026, 08:51 ET 晶泰AI賦能管線再迎臨床轉化：萊芒生物「千分之一」劑量CAR-T療法獲FDA臨床批准
Ltd）是一家處於臨床階段的免疫代謝創新藥物研發公司，由瑞士洛桑聯邦理工學院（EPFL）唐力教授團隊聯合晶泰科技共同創立。基於免疫代謝重編程（META 10）+前沿人工智能（AI）的創新技術，公司專注於研發代謝增強型腫瘤免疫治療藥物。公司核心技術 META 10 展示出治癒實體腫瘤的巨大潛力，相關成果發表於 Nature、Nature Biotechnology、Nature Immunology 和 Lancet Haematology 等國際頂級學術期刊，並申請了多項 PCT 專利和中國發明專利。2022 年以來，公司累計獲得超 4 億元風險投資和項目資助，榮膺 2025 年全國 「顛覆性技術創新」 大賽最高獎項等數十項生物醫藥領域國家或省市級獎項，併入選國家重點研發計劃
More news about: 晶泰科技
Mar 18, 2026, 08:00 ET Elaris Secures Exclusive Global License from Valneva for C. difficile Vaccine Program
VIENNA, Austria, March 18, 2026 /PRNewswire/ -- Elaris FlexCo ("Elaris"), an Austrian biotechnology company developing vaccines against serious bacterial infections, today announced an exclusive global license agreement with Valneva SE (Nasdaq:
More news about: Elaris
Mar 18, 2026, 08:00 ET IsomAb appoints Dr Philip Brainin as Chief Executive Officer
NOTTINGHAM, England, March 18, 2026 /PRNewswire/ -- IsomAb Ltd, a UK-based biotechnology company, today announced the appointment of Dr Philip Brainin as Chief Executive Officer (CEO) and member of the Board of Directors. IsomAb
More news about: IsomAb
Mar 18, 2026, 08:00 ET Sapience Therapeutics to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026
TARRYTOWN, N.Y., March 18, 2026 /PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, today
More news about: Sapience Therapeutics, Inc.
Mar 18, 2026, 08:00 ET MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control
CAMBRIDGE, Mass., March 18, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that the Institutional Review Board (IRB) at Clinical Pharmacology of
More news about: MetaVia Inc.
Mar 18, 2026, 08:00 ET SK bioscience Secures Funding to Advance RSV Preventive Antibody Development with RIGHT Foundation Support
this month from the Gates Medical Research Institute (Gates MRI), a nonprofit medical research organization. The candidate was designed by U.S. biotechnology company Adimab in collaboration with Gates MRI, which completed early research and a Phase 1a clinical trial. SK bioscience will oversee subsequent
More news about: SK bioscience
Mar 18, 2026, 07:01 ET Kali Therapeutics Announces First Patient Dosed in Phase 1a Clinical Trial of KT501 for Rheumatoid Arthritis
SAN MATEO, Calif., March 18, 2026 /PRNewswire/ -- Kali Therapeutics, a clinical-stage biotechnology company pioneering next-generation immune-resetting therapies, today announced that dosing is underway for the first cohort of patients in its Phase
More news about: Kali Therapeutics
Mar 18, 2026, 07:00 ET GentiBio Announces First Participant Dosed in POLARIS Phase 1 Clinical Trial of GNTI-122 in Recently Diagnosed Type 1 Diabetes
CAMBRIDGE, Mass., March 18, 2026 /PRNewswire/ -- GentiBio, Inc., a clinical-stage biotechnology company pioneering engineered, antigen-specific regulatory T cell (EngTreg) therapies, today announced that the first participant has been dosed
More news about: GentiBio, Inc.
Mar 18, 2026, 01:01 ET GCC Ultra-Premium Beauty & Personal Care Market to Grow at a CAGR of 10.99% During 2026-2032, Reports MarkNtel Advisors
demand, luxury skincare brands are investing heavily in research and product innovation to develop sophisticated formulations that incorporate biotechnology-derived ingredients, rare botanical extracts, and clinically tested active compounds. These premium formulations often promise visible skin improvements
More news about: MarkNtel Advisors
Mar 17, 2026, 16:46 ET Brenig Therapeutics Announces Oral Presentation of Phase 1 Data for BT-267 at AD/PD™ 2026, and Provides Updates on BT-409, its NLRP3 Inhibitor Program
BOSTON, March 17, 2026 /PRNewswire/ -- Brenig Therapeutics, Inc. (Brenig), a clinical-stage biotechnology company advancing small-molecule therapies for neurologic diseases, today announced that Tien Dam, MD, Chief Medical Officer, will present interim
More news about: Brenig Therapeutics Inc
Mar 17, 2026, 12:11 ET Longevity Medical Institute® Publishes Systematic Review of Stem Cell Safety Based on Landmark Human Clinical Trials
services, full-body AI-enhanced MRI imaging, and biotechnology infrastructure within one coordinated environment.Longevity Medical Institute recently announced the opening of a federally licensed Stem Cell and Regenerative Medicine Biotechnology Laboratory operating under COFEPRIS, Mexico's national
More news about: Longevity Medical Institute LLC
Mar 17, 2026, 10:56 ET Nexus Health, Part of The Lockwood Group, Welcomes Stratis Group to Expand Commercialization and Market Access Capabilities
specializing in commercialization strategy, market access, patient services, HEOR, field reimbursement management (FRM), and analytics for pharmaceutical, biotechnology, and physician network clients. The acquisition strengthens Nexus Health's ability to deliver integrated, data-driven solutions that support clients
More news about: Nexus Health
Mar 17, 2026, 10:15 ET Personal Care and Cosmetics Microalgae Market to Reach USD 117 Million by 2035, Driven by Clean Beauty, Biotech Innovation, and Sustainable Skincare Demand
AmericaNorth America holds the dominant market share, supported by strong demand for clean-label skincare and increased investment in biotechnology-driven cosmetic solutions. The United States and Canada are leading adopters, with brands incorporating ingredients like spirulina, chlorella, and
More news about: Future Market Insights
Mar 17, 2026, 10:08 ET Cellipont Bioservices and BobcatBio Announce Strategic Collaboration to Advance Macrophage Cell Therapy for Solid Tumors
therapy Contract Development and Manufacturing Organization (CDMO), today announced a strategic collaboration with BobcatBio, a clinical-stage biotechnology company that is pioneering the development of RB-1355, a first of its kind cellular therapy that leverages the versatility and power of a patient's
More news about: Cellipont Bioservices
Mar 17, 2026, 10:01 ET Epidermolysis Bullosa Market Set for Significant Upswing During the Forecast Period (2025-2034) Amid Rising Therapeutic Advancements | DelveInsight
Biosciences), EBESANAR (RHEACELL and AOP Health), Redasemtide (SHIONOGI/StemRIM), KB803 (Krystal Biotech), AGLE-102 (Aegle Therapeutics), AC-203 (TWi Biotechnology), and others in the coming years.LAS VEGAS, March 17, 2026
More news about: DelveInsight Business Research, LLP
Mar 17, 2026, 09:06 ET Prendio and BioProcure Appoint Life Sciences Technology Leader Larry Birch as Chief Executive Officer
deepening relationships with biotechnology and pharmaceutical customers, and developing new solutions that help life sciences organizations manage purchasing, financial operations, and supplier relationships more effectively.For more than two decades, biotechnology companies have relied on Prendio
More news about: Prendio-BioProcure
Mar 17, 2026, 09:02 ET ISPE Announces its 2026 ISPE Europe Annual Conference Keynote Speakers
confronts simultaneous shifts in regulatory frameworks, digitalization, and advanced therapeutic development," said David Estapé, Technology Manager Biotechnology, CRB Group GmbH. "Its program offers a robust, case‑driven examination of how AI‑enabled decision systems, data‑centric compliance models, and next‑generation
More news about: ISPE
Mar 17, 2026, 09:01 ET Co-PSMA data presented at EAU Annual Congress 2026 with manuscript accepted for publication in the European Urology journal
prostate cancer patients with BCR."Clarity's Executive Chairperson, Dr Alan Taylor, commented, "Science underpins the entirety of our biotechnology sector, and as a science-driven organisation, nothing makes us more proud than to see our products progress from the Australian benchtop to now
More news about: Clarity Pharmaceuticals
Mar 17, 2026, 09:00 ET Apertura Gene Therapy and Viralgen Announce Strategic Collaboration to Manufacture TfR1 CapX, a Next-Generation Capsid for Gene Therapies Designed to Treat Central Nervous System Diseases
NEW YORK and SAN SEBASTIÁN, Spain, March 17, 2026 /PRNewswire/ -- Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, and Viralgen, a leading contract development and manufacturing
More news about: Viralgen
Mar 17, 2026, 09:00 ET Apertura Gene Therapy and Viralgen Announce Strategic Collaboration to Manufacture TfR1 CapX, a Next-Generation Capsid for Gene Therapies Designed to Treat Central Nervous System Diseases
NEW YORK and SAN SEBASTIÁN, Spain, March 17, 2026 /PRNewswire/ -- Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, and Viralgen, a leading contract development and manufacturing
More news about: Viralgen
Mar 17, 2026, 08:30 ET Dalriada Drug Discovery and Topos Bio Announce Collaboration to Advance Drug Discovery for Intrinsically Disordered Proteins
discovery organization supporting small-molecule programs from hit identification through lead optimization, and Topos Bio ("Topos"), an AI-native biotechnology company developing therapeutics for intrinsically disordered proteins (IDPs), today announced a research collaboration to accelerate experimental
More news about: Dalriada Drug Discovery
Mar 17, 2026, 08:00 ET Flagship Pioneering Appoints Eric Topol as Academic Advisor to Advance Preemptive Health and Medicine Initiative
Sana Biotechnology,
More news about: Flagship Pioneering
Mar 17, 2026, 08:00 ET Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306
it has entered into licensing and equity agreements (the "Agreements") with R1 Therapeutics, Inc. ("R1"). R1 is a newly launched clinical-stage biotechnology company that recently completed an oversubscribed Series A financing of $77.5M. R1 is backed by major global kidney care providers, DaVita, one
More news about: Alebund Pharmaceuticals
Mar 17, 2026, 07:32 ET VST BIO Corporation Announces Series A Financing to Advance VB-001 and Adds William Sessa to Board of Directors
SAN DIEGO, March 17, 2026 /PRNewswire/ -- VST BIO Corporation ("VST BIO"), a biotechnology company developing stroke therapeutics, announces the closing of its Series A financing, led by Coefficient Giving, a philanthropic funder and advisor
More news about: VST Bio Corporation
Mar 17, 2026, 06:38 ET MGI Tech and Predica Diagnostics Accelerate Cervical Cancer Screening on DNBSEQ Platforms
focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and a full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare, and various
More news about: MGI Tech Co., Ltd.